Close Menu

Precision Oncology Business News

Financial news, mergers and acquisitions, partnerships, and alliances.

The firms are developing a kit-based CDx to detect NTRK gene fusions, including NTRK1, NTRK2 and NTRK3, for Bayer's Vitrakvi cancer treatment.

Under this agreement, Bixink will be responsible for seeking regulatory approval for Nerlynx in South Korea, and Puma could receive payments of up to $6 million from drug sales.

WUSTL will evaluate BostonGene's software, which integrates data from NGS with immunofluorescence imaging to profile tumors and their microenvironments.

Under the deal, the companies aim to develop a companion diagnostic for Bayer's solid tumor drug larotrectinib for the Chinese market.

Data amassed by analytics firm Diaceutics suggests fewer patients are coming into healthcare facilities and missing the chance for diagnosis, molecular testing, and treatment.